GlassScriptPhysician profile
Daniel F Child
NPI 1801233887
$3,678.34
in general payments reported to CMS, 2019-2025
33 companies · $941 in 2025
The $941 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $117 · 2021: $686 · 2022: $400 · 2023: $534 · 2024: $430 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,904.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $669.23 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $330.01 | 2019-2025 | |
| Novo Nordisk INC | $259.70 | 2019-2025 | Ozempic |
| Otsuka America Pharmaceutical, INC. | $255.97 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $246.31 | 2021-2025 | Ubrelvy, Vraylar |
| Vanda Pharmaceuticals INC. | $223.56 | 2025 | Fanapt |
| Lilly USA, LLC | $198.11 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $196.74 | 2019-2025 | Otezla, Repatha, Otezla |
| Sanofi Pasteur INC. | $194.21 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.69 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $127.54 | 2019-2024 | Veozah |
| Exact Sciences Corporation | $117.81 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $88.13 | 2021-2025 | Shingrix, Bexsero, Arexvy |
| Allergan, INC. | $67.40 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $62.45 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $58.69 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $52.60 | 2019 | |
| Organogenesis INC. | $40.22 | 2025 | Cygnus Dual |
| Biohaven Pharmaceutical Holding Company LTD. | $38.31 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $37.93 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $37.44 | 2019-2023 | |
| Eisai INC. | $29.33 | 2021 | |
| Digital Diagnostics INC. | $28.61 | 2019 | |
| Sanofi-Aventis U.S. LLC | $27.07 | 2019 | |
| Merck Sharp & Dohme LLC | $22.65 | 2021 | |
| Irhythm Technologies, INC. | $22.47 | 2019 | |
| Inspire Medical Systems, INC. | $22.20 | 2025 | Inspire |
| Dexcom, INC. | $20.83 | 2023 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $15.56 | 2021 | |
| Ge Healthcare | $14.90 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.73 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.50 | 2019 | |
| Bioventus LLC | $12.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Child listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.